Subscribe to our Newsletters !!
Climate change is very disruptive to the Amazon ra
By 2024, there are certain things you need to do i
Insects that are given more attention and reverenc
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Bharat Biotech announced its prospective COVID-19 vaccine — Covaxin — was discovered to generate strong immune responses in rhesus macaques or monkeys, preventing infection and disease even upon high levels of exposure to live SARS-CoV-2 virus.
The Hyderabad-based firm said data from the study on primates substantiate the immunogenicity of the vaccine candidate.
Covaxin developed by Indian Council of Medical Research (ICMR) and Bharat Biotech, is being tested at 12 institutes across India. Currently, the vaccine that contains inactivated SARS-CoV-2 virus is undergoing Phase II clinical trials.
Twenty macaques were divided into four groups of five animals each, it said.
One group was administered with placebo, while three groups were immunised with three different vaccine candidates at zero and 14 days.
All the macaques were challenged with SARS-CoV-2 14 days after the second dose. The results demonstrated that monkeys who received Covaxin have shown protective efficacy, increase in SARS-CoV-2 specific IgG and neutralising anti-bodies, reducing replication of this virus in the nasal cavity, throat, and lung tissues of the monkeys.
The company said that there was no signs of pneumonia was detected by histopathological examination in vaccinated groups, unlike the placebo group, which revealed features of interstitial pneumonia and localisation of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry.
The research results were published in preprint server, so it is not peer reviewed.
“Bharat Biotech proudly announces the animal study results of COVAXIN – These results reveal that the protective efficacy in a live viral challenge model,” Bharat Biotech tweeted on September 11.
